Northwestern Medicine First in Aclarion’s Clarity Trial
Aclarion, Inc. launched its pivotal CLARITY trial at Northwestern Medicine, a leading clinical trial research center. The CLARITY trial...
Jon Napitupulu
FDA Approves Lipella’s LP-310 for Oral Lichen Planus
Lipella Pharmaceuticals (Nasdaq: LIPO) has received FDA approval for an Expanded Access Program (EAP) for LP-310, an oral rinse...
Vaxxas Appoints Global Vaccine Experts for Needle-Free Trials
Vaxxas, a clinical-stage biotech company, has appointed three prominent vaccine experts as advisors to guide product development and strategy....
AgelessRx Launches Oral GLP-1 Drops for Metabolic Health
AgelessRx has launched oral sublingual drops for the GLP-1 receptor agonists Semaglutide and Tirzepatide, offering a non-injectable alternative for...
Enveda’s First-in-Class ENV-294 for Asthma: A Breakthrough
Enveda Biosciences is testing its lead drug candidate, ENV-294, for asthma, marking its second clinical application after atopic dermatitis....
BioXcel: Business & Clinical Update
BioXcel Therapeutics provided an update on its late-stage clinical trials for BXCL501, a drug for acute agitation, and highlighted...
Zenocutuzumab Efficacy in NRG1+ Cancer: Groundbreaking Results
Merus N.V. announced that the New England Journal of Medicine (NEJM) published positive results from the phase 2 eNRGy...
Ziftomenib Shows Promise in AML Monotherapy & Combination Trials
Kura Oncology and Kyowa Kirin announced positive topline results from the KOMET-001 Phase 2 trial of ziftomenib, an oral...
Ozempic’s Chronic Kidney Disease Benefits Highlighted by Nephrologists
Spherix Global Insights’ analysis of over 1,000 patient charts reveals a significant increase in the use of GLP-1 receptor...
Arbor Biotechnologies’ ABO-101 Gets FDA Orphan Drug, Rare Pediatric Disease Designations
Arbor Biotechnologies received Orphan Drug and Rare Pediatric Disease designations from the U.S. FDA for ABO-101, a gene editing...